Tags : Pivotal bioVenture Partners

Series D

Exscientia secures £162 million Series D investment led by SoftBank

Exscientia announces investment of up to $525M Proceeds to continue expansion of proprietary pipeline and end-to-end AI drug discovery capabilities $225 million Series D round closed with access up to an additional $300 million at Exscientia’s discretion Financing led by SoftBank Vision Fund 2 27th April, 2021, Oxford, UK – Exscientia, a clinical stage pharmatech company using […]Read More